कंपनी का अवलोकन
ADMA Biologics, Inc. operates as a biopharmaceutical entity dedicated to the development, manufacturing, and marketing of specialty plasma-derived biologics designed to treat immune deficiencies and infectious diseases within the United States and international markets. The company functions within the Healthcare sector and specifically in the Biotechnology industry, a domain characterized by high R&D requirements and specialized production capabilities for therapeutic proteins. In terms of operational scale, the firm employs approximately 640 individuals and holds a total market capitalization of $2.37B, while generating annual revenue (TTM) of $510.17M. These valuation and revenue figures indicate that ADMA holds a significant position in its niche, reflecting a mature market presence supported by a substantial workforce and a robust top-line performance that supports its ongoing R&D and manufacturing activities.
वित्तीय स्वास्थ्य
The company reported a revenue of $510.17M for the trailing twelve months, accompanied by a net income of $146.93M and an EBITDA of $199.54M. The substantial gap between the $510.17M revenue and the $146.93M net income reveals a cost structure where expenses, likely including significant operating costs or one-time charges, consume nearly 71% of total revenue before reaching the bottom line, despite the high gross margin. However, the free cash flow stands at $-18,154,876, indicating a temporary negative liquidity position where cash outflows for operations or capital expenditures exceeded cash generated from sales, which impacts immediate financial flexibility for large-scale expansions. The gross margin is reported at 57.4%, suggesting strong pricing power or cost efficiencies in the manufacturing of plasma-derived products, while the operating margin is -123.4%, signaling that operating expenses currently exceed gross profit significantly, and the profit margin is 28.8%, which reflects the bottom-line profitability efficiency relative to total sales. Regarding the balance sheet, total cash assets amount to $55.92B while total debt is listed at $97.67B, resulting in a debt-to-equity ratio of 110.67, which indicates a highly leveraged position where liabilities exceed equity. The current ratio is 6.71, demonstrating an exceptionally strong short-term liquidity position that ensures the company can easily meet its short-term obligations with its current assets. Return on Equity is 35.6% and Return on Assets is 21.5%, metrics that reveal highly effective management in generating returns from shareholders' capital and total assets respectively, despite the leveraged balance sheet structure.
मूल्यांकन आकलन
The trailing P/E ratio is 16.57, whereas the forward P/E is 7.20, a significant difference implying that the market expects a substantial increase in future earnings relative to current levels, potentially driven by anticipated cost reductions or revenue scaling. The price-to-book ratio is 4.95, which indicates that the stock trades at a considerable premium over its book value, reflecting investor confidence in the company's intangible assets, brand, and future growth potential within the biotechnology sector. Alternative valuation metrics show a price-to-sales ratio of 4.64 and an EV/EBITDA of 221.08, suggesting that the market values the company highly relative to its sales and earnings before interest, taxes, depreciation, and amortization, often seen in growth-oriented biotech firms with high cash reserves. The 52-week high is $25.67 and the 52-week low is $7.21, meaning the current price metrics sit in a wide trading range that highlights significant volatility over the past year. The beta value is 0.82, indicating that the stock's price volatility is lower than the broader market, suggesting it may be less sensitive to general market fluctuations compared to the S&P 500.
Growth & Income
The revenue growth year-over-year is 15.9%, while earnings growth is listed as N/A, which implies that while top-line sales are expanding robustly, the consistency of bottom-line profitability growth is not currently quantified in the available metrics. As a non-dividend payer, the company does not distribute a dividend yield or maintain a payout ratio, as indicated by the 0.0% figure, meaning the firm reinvests all earnings back into research, development, and manufacturing capabilities rather than returning cash to shareholders. This reinvestment strategy is typical for biotechnology companies in the growth phase, prioritizing future product pipelines over immediate income distribution to shareholders. The overall growth and income profile reflects a company focused on capital appreciation through revenue expansion and asset accumulation rather than providing current income streams via dividends.